Icagen (NASDAQ:ICGN) reported revenues for the Q2 were $1.0 million, as compared to 2.3 million during the same period in 2010.
P. Kay Wagoner, CEO of Icagen noted, "Subsequent to the end of the second quarter, we were pleased to recently announce Pfizer's agreement to acquire Icagen. We are working towards the completion of this transaction, which we expect will be accomplished before the end of the year."
